A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement
- 1 January 1991
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 28 (6) , 465-469
- https://doi.org/10.1007/bf00685824
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancerCancer Chemotherapy and Pharmacology, 1991
- Anthracycline Pharmacokinetics: Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin)Acta Oncologica, 1990
- Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effectsClinical Pharmacology & Therapeutics, 1989
- Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicinClinical Pharmacology & Therapeutics, 1989
- Epirubicin and doxorubicin comparative metabolism and pharmacokineticsCancer Chemotherapy and Pharmacology, 1988
- Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.Journal of Clinical Oncology, 1988
- Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administrationEuropean Journal of Clinical Pharmacology, 1986
- Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patientsEuropean Journal of Cancer and Clinical Oncology, 1985
- COMPARATIVE PHARMACOKINETICS AND METABOLISM OF DOXORUBICIN AND EPIRUBICIN IN PATIENTS WITH METASTATIC BREAST-CANCER1985
- SENSITIVE AND SPECIFIC DETERMINATION OF THE NEW ANTHRACYCLINE ANALOG 4'-EPIDOXORUBICIN AND ITS METABOLITES BY HIGH-PRESSURE LIQUID-CHROMATOGRAPHY1984